Назад к статьям

Источники литературы

1. Reid G. Regulatory and clinical aspects of dairy probiotics. FAO/WHO Expert Consultation on Evaluation of Health and Nutritional Properties of Powder Milk with Live Lactic Acid Bacteria. Cordoba, Argentina, 2001: 1-34.

2. Hoesl C.E., Altwein J.E. The probiotic approach: an alternative treatment option in urology. Eur Urol, 2005; 47: 288–96.

3. Gibson G.R., Roberfroid M.B. Dietary modulation of the human colonic micro-biota: introducing the concept of prebiotics. J Nutr 1995: 125: 1401-12.

4. Tanaka R., Takayama H., Morotomi М. e a. Effect of administration TOS and Bifidobacterium breve 4006 on the human fecal flora. Bifidobacteria microflora 1983; 2: 17-24.

5. Roberfroid M.B. Prebiotics and probiotics: are they functional foods? Am J Clin Nutr 2000: 71 (Suppl 6): 1682S-87S.

6. Van Loo J., Cummings J., Delzenne N., e. a. Functional food properties of non-digestible oligosaccharides: a consensus report from the HVDO project (DGXII AIRII-CT94-1095). Br J Nutr. 1999; 81(2): 121-32.

7. Rowland I.R., Tanaka R. The effects of transgalactosylated oligosaccharides on gut flora metabolism in rats associated with a human faecal microflora. J AppI Bacteriol 1993: 74: 667-74.

8. Eaton T.J., Gasson M.J. Molecular screening of Enterococcus virulence determinants and potential for genetic exchange between food and medical isolates. Appl Environ Microbiol. 2001; 67(4): 1628-35.

9. Holzapfel W.H., Haberer P., Geisen R., et al. Taxonomy and important features of probiotic microorganisms in food and nutrition. Am J Clin Nutr 2001;73(2 Suppl):365S-73S.

10. Walker R., Buckley M. Probiotic microbes: the scientific basis. A report from the American Academy of Microbiology, 2006.

11. Marcos A., Wärnberg J., Nova E., et al.The effect of milk fermented by yogurt cultures plus Lactobacillus casei DN-114001 on the immune response of subjects under academic examination stress. Eur J Nutr. 2004; 43(6): 381-9.

12. Monachese M., Burton J.P., Reid G. Bioremediation and tolerance of humans to heavy metals through microbial processes: a potential role for probiotics? Appl Environ Microbiol. 2012; 78(18): 6397-404.

13. Guidelines for the Evaluation of Probiotics in Food. Joint FAO/WHO (Food and Agriculture Organization/World Health Organisation) Working Group. London, Ontario, Canada: 2002.

14. Saavedra J. M. Clinical applications ofprobiotic agents. Am J Clin Nutr. 2001; 73(6): 1147S-51S.

15. Madsen K. I. The use ofprobiotics in gastrointestinal disease. Can J Gastroenterol. 2001; 15 (S12): 817-22.

16. Kailasapathy K., Chin J. Survival and therapeutic potential of probiotic organisms with reference to Lactobacillus acidophilus and Bifidobacterium spp. Immunol Cell Biol. 2000; 78(1): 80-8.

17. Андреева И.В., Стецюк О.У. О штаммоспецифичности пробиотиков. Клин. Микробиол. Антимикроб. Химиотер. 2010; 12 (3): 253-254.

18. Adams M. R., Marteau P. On the safety of lactic acid bacteria from food. Int J Food Microbiol. 1995; 27: 263-4.

19. Naidu A. S., Bidlack W. RClemens., R. A. Probiotic spectra of lactic acid bacteria (LAB). Crit Rev Food Sci Nutr 1999; 39:13-126.

20. Reid, G. Safety of Lactobacillus strains as probiotic agents. Clin. Infect. Dis 2002; 35: 349-50.

21. Doron S., Snydman D.R. Risk and safety of probiotics. Clin Infect Dis. 2015; 60 Suppl 2: S129-34.

22. Salminen S, von Wright A, Morelli L, Marteau P, Brassart D, de Vos WM, et al. Demonstration of safety of probiotics - a review. Int J Food Microbiol 1998; 44: 93-106.

23. Borriello S.P., Hammes W.P., Holzapfel W., e a. Safety of probiotics that contain lactobacilli or bifidobacteria. Clin Infect Dis 2003; 36: 775–80.

24. Marteau P, Seksik P, Jian R.:Probiotics and health: new facts and ideas. Curr Opin Biotechnol. 2002; 13(5): 486-9.

25. Mackay AD, Taylor MB, Kibbler CC, Hamilton-Miller JMT. Lactobacillusendocarditis caused by a probiotic organism. Clin Microbiol Infect 1999;5:290-2.

26. Rautio M., Jousimies-Somer H., Kauma H., e. a. Liver abscess due to a Lactobacillus rhamnosus strain indistinguishable from L. rhamnosus strain GG. Clin Infect Dis 1999; 28: 1159-60.

27. Salminen M.K., Rautelin H., Tynkkynen S., e.a. Lactobacillus bacteremia, clinical significance, and patient outcome, with special focus on probiotic L. rhamnosus GG. Clin Infect Dis. 2004; 38(1):62-9.

28. Land M.H., Rouster-Stevens K., Woods C.R., e.a. Lactobacillus sepsis associated with probiotic therapy. Pediatrics. 2005; 115(1): 178-81.

29. De Groote M.A., Frank D.N., Dowell E., e.a. Lactobacillus rhamnosus GG bacteremia associated with probiotic use in a child with short gut syndrome. Pediatr Infect Dis J. 2005; 24(3): 278-80.

30. Sadowska-Krawczenko I., Paprzycka M., Korbal P., et al. Lactobacillus rhamnosus GG suspected infection in a newborn with intrauterine growth restriction. Benef Microbes. 2014; 5(4): 397-402.

31. Vahabnezhad E., Mochon A.B., Wozniak L.J., Ziring D.A. Lactobacillus bacteremia associated with probiotic use in a pediatric patient with ulcerative colitis. J Clin Gastroenterol. 2013; 47(5): 437-9.

32. Kubiszewska I., Januszewska M., Rybka J., Gackowska L. Lactic acid bacteria and health: are probiotics safe for human? Postepy Hig Med Dosw (Online). 2014; 68: 1325-34.

33. Hennequin C., Kauffmann-Lacroix C., Jobert A., e.a. Possible role of catheters in Saccharomyces boulardii fungemia. Eur J Clin Microbiol Infect Dis. 2000; 19(1): 16-20.

34. Cherifi S., Cherifi S., Robberecht J., Miendje Y. Saccharomyces cerevisiae fungemia in an elderly patient with Clostridium difficile colitis. Acta Clin Belg. 2004; 59(4): 223-4.

35. Riquelme A.J., Calvo M.A., Guzman A.M., e.a. Saccharomyces cerevisiae fungemia after Saccharomyces boulardii treatment in immunocompromised patients. J Clin Gastroenterol. 2003; 36(1): 41-3.

36. Lestin F., Pertschy A., Rimek D. Fungemia after oral treatment with Saccharomyces boulardii in a patient with multiple comorbidities. Dtsch Med Wochenschr. 2003 Nov 28;128(48):2531-3.

37. Thygesen J.B., Glerup H., Tarp B. Saccharomyces boulardii fungemia caused by treatment with a probioticum. BMJ Case Rep. 2012; pii: bcr0620114412.

38. Eren Z., Gurol Y., Sonmezoglu M., et al. Saccharomyces cerevisiae fungemia in an elderly patient following probiotic treatment. Mikrobiyol Bul. 2014; 48(2): 351-5.

39. Santino I., Alari A., Bono S., et al. Saccharomyces cerevisiae fungemia, a possible consequence of the treatment of Clostridium difficile colitis with a probioticum. Int J Immunopathol Pharmacol. 2014; 27(1): 143-6.

40. Munoz Р., Bouza E., Cuenca-Estrella M., e. a. Saccharomyces cerevisiae fungemia: an emerging infectious disease. Clin Infect Dis 2005; 40(11):1625-34.

41. Oggioni M.R., Pozzi G., Balensin P.E., e.a. Recurrent septicemia in an immunocompromised patient due to probiotic strains of Bacillus subtilis. J Clin Microbiol 1998; 36: 325–6.

42. Richard V., Auwera P., Snoeck R., e.a. Nosocomial bacteremia caused by Bacillus species. Eur J Clin Microbiol Infect Dis 1988; 7: 783–5.

43. Gardiner D., Murphey S., Ossman E., Jungkind D. Prevalence and acquisition of vancomycin-resistant enterococci in a medical intensive care unit. Infect Control Hosp Epidemiol, 2002; 23: 466-8.

44. Szajewska H, et al. Use of Probiotics for Management of Acute Gastroenteritis: A Position Paper by the ESPGHAN Working Group for Probiotics and Prebiotics. JPGN 2014; 58 (4): 531-9.

45. Salminen M.K., Tynkkynen S., Rautelin H., e.a. Lactobacillus bacteremia during a rapid increase in probiotic use of Lactobacillus rhamnosus GG in Finland. Clin Infect Dis. 2002; 35(10): 1155-60.

46. Reid G., Jass J., Sebulski M.T., McCormick J.K. Potential uses of probiotics in clinical practice. Clin Microbiol Rev. 2003; 16(4): 658-72.

47. Allen S.J., Martinez E.G., Gregorio G.V., Dans L.F. Probiotics for treating acute infectious diarrhoea. Cochrane Database Syst Rev. 2010 Nov 10;11:CD003048.

48. Szajewska H., Skórka A., Ruszczyński M., Gieruszczak-Białek D. Meta-analysis: Lactobacillus GG for treating acute gastroenteritis in children--updated analysis of randomised controlled trials. Aliment Pharmacol Ther. 2013; 38(5): 467-76.

49. de la Cabada Bauche J, Dupont HL. New Developments in Traveler's Diarrhea. Gastroenterol Hepatol (N Y). 2011; 7(2): 88-95.

50. Connor B.A., Landzberg B.R. Prevention and treatment of acute traveler's diarrhea. Infect Med 2004; 21(1): 18-9.

51. McFarland L.V. Meta-analysis of probiotics for the prevention of traveler's diarrhea. Travel Med Infect Dis. 2007; 5(2): 97-105.

52. Cremonini F., Di Caro S., Nista E.C., e.a. Meta-analysis: the effect of probiotic administration on antibiotic-associated diarrhoea. Aliment Pharmacol Ther. 2002; 16(8): 1461-7.

53. D'Souza A.L., Rajkumar C., Cooke J., Bulpitt C.J. Probiotics in prevention of antibiotic associated diarrhoea: meta-analysis. BMJ. 2002; 324(7350): 1361.

54. Hempel S., Newberry S.J., Maher A.R., et al. Probiotics for the prevention and treatment of antibiotic-associated diarrhea: a systematic review and meta-analysis. Ann Intern Med. 2012; 157(12): 878-88.

55. Castagliuolo I., Riegler M.F., Valenick L., еt аl. Saccharomyces boulardii protease inhibits the effects of Clostridium difficile toxins A and B in human colonic mucosa. Infect Immun 1999; 67(1): 302-7.

56. Boyanova L., Mentis A., Gubina M., e.a. The status of antimicrobial resistance of Helicobacter pylori in Еastern Europe. Clin Microbiol Infect 2002; 8 (7): 388-96

57. Tong J.L., Ran Z.H., Shen J., e.a. Meta-analysis: the effect of supplementation with probiotics on eradication rates and adverse events during Helicobacter pylori eradication therapy. Aliment Pharmacol Ther. 2007; 25(2): 155-68.

58. Zou J, Dong J, Yu X. Meta-analysis: Lactobacillus containing quadruple therapy versus standard triple first-line therapy for Helicobacter pylori eradication. Helicobacter. 2009; 14(5): 97-107.

59. Chenoll E., Casinon B., Bataller E. et al. Novel probiotic Bifidobacterium bifidum CECT 7366 strain active against the pathogenic bacterium Helicobacter pylori. Applied and environmental microbiology, 2011: 1335-1343.

60. Dimidi E., Christodoulides S., Fragkos K.C., et al. The effect of probiotics on functional constipation in adults: a systematic review and meta-analysis of randomized controlled trials. Am J Clin Nutr. 2014; 100(4): 1075-84.

61. Saavedra J.M., Abi-Hanna A., Moore N., et al. Long-term consumption of infant formulas containing live probiotic bacteria: tolerance and safety. Am J Clin Nutr. 2004; 79(2): 261-7.

62. Kianifar H., Ahanchian H., Grover Z., et al. Synbiotic in the management of infantile colic: A randomised controlled trial. J Paediatr Child Health. 2014; 50(10): 801-5.

63. Indrio F., Di Mauro A., Riezzo G., et al. Prophylactic Use of a Probiotic in the Prevention of Colic, Regurgitation, and Functional Constipation: A Randomized Clinical Trial. JAMA Pediatr. 2014; 168(3): 228-33.

64. Wong V.W., Won G.L., Chim A.M., et al. Treatment of nonalcoholic steatohepatitis with probiotics. A proof-of-concept study. Ann Hepatol. 2013; 12(2): 256-62.

65. Reid G., Bruce A. W., Fraser N., e.a. Oral probiotics can resolve urogenital infections. FEMS Immunol. Med. Microbiol. 2001; 30: 49-52.

66. Isolauri E. Dietary modification of atopic disease: Use of probiotics in the prevention of atopic dermatitis. Curr Allergy Asthma Rep. 2004; 4(4): 270-5.

67. Schmidt W.P. Model of the epidemic of childhood atopy. Med Sci Monit. 2004; 10(2): HY5.

68. Kalliomaki M., Isolauri E. Role of intestinal flora in the development of allergy // Curr Opin Allergy Clin Immunol. 2003; 3(1): 15-20.

69. Rosenfeldt V., Benfeldt E., Valerius N.H., et al. Effect of probiotics on gastrointestinal symptoms and small intestinal permeability in children with atopic dermatitis. J Pediatr. 2004; 145(5): 612-6.

70. Majamaa H., Isolauri E. Probiotics: a novel approach in the management of food allergy. J Allergy Clin Immunol. 1997; 99(2): 179-85.

71. No author indicated. Research suggests potential role for probiotics in treating allergy. Infectious diseases in children 2003; 3: 72.

72. Kalliomaki M., Salminen S., Poussa T., et al. Probiotics and prevention of atopic disease: 4-year follow-up of a randomised placebo-controlled trial. Lancet. 2003; 361 (9372): 1869-71.

73. Rautava S., Kalliomaki M., Isolauri E. Probiotics during pregnancy and breast-feeding might confer immnomodulatory protection against atopic disease in the infant. J Allergy Clin Immunol. 2002; 109(1): 119-21.

74. Hanifin J.M., Cooper K.D., Ho V.C., et al. Guidelines of care for atopic dermatitis, developed in accordance with the American Academy of Dermatology (AAD)/American Academy of Dermatology Association «Administrative Regulations for Evidence-Based Clinical Practice Guidelines». J Am Acad Dermatol. 2004; 50(3): 391-404.

75. Pelucchi C., Chatenoud L., Turati F., et al. Probiotics supplementation during pregnancy or infancy for the prevention of atopic dermatitis: a meta-analysis. Epidemiology. 2012; 23(3): 402-14.

76. Foolad N., Brezinski E.A., Chase E.P., Armstrong A.W. Effect of nutrient supplementation on atopic dermatitis in children: a systematic review of probiotics, prebiotics, formula, and fatty acids. JAMA Dermatol. 2013; 149(3): 350-5.

77. Isolauri E., Arvola T., Sutas Y., et al. Probiotics in the management of atopic eczema. Clin Exp Allergy. 2000; 30(11): 1604-10.

78. Viljanen M., Savilahti E., Haahtela T., et al. Probiotics in the treatment of atopic eczema/dermatitis syndrome in infants: a double-blind placebo-controlled trial. Allergy. 2005; 60(4): 494-500.

79. Michail S.K., Stolfi A., Johnson T., Onady G.M. Efficacy of probiotics in the treatment of pediatric atopic dermatitis: a meta-analysis of randomized controlled trials. Ann Allergy Asthma Immunol. 2008; 101(5): 508-16.

80. Collet J.P., Burtin P., Gillet J., еt аl. Risk of infectious diseases in children attending different types of day-care setting. Respiration 1994; 61(suppl 1): 16-9.

81. Nafstad P., Hagen J.A., Oie L., et al. Day care centers and respiratory health. Pediatrics. 1999; 103: 753-8.

82. Hatakka K., Savilahti E., Ponka A., et al. Effect of long term consumption of probiotic milk on infections in children attending day care centres: double blind, randomised trial. BMJ. 2001; 322(7298): 1327.

83. Hojsak I., Snovak N., Abdović S., et al. Lactobacillus GG in the prevention of gastrointestinal and respiratory tract infections in children who attend day care centers: a randomized, double-blind, placebo-controlled trial. Clin Nutr. 2010; 29(3): 312-6.

84. Rautava S., Arvilommi H., Isolauri E. Specific probiotics in enhancing maturation of IgA responses in formula-fed infants. Pediatr Res. 2006; 60(2): 221-4.

85. Cazzola M., Pham-Thi N., Kerihuel J.C., Durand H., Bohbot S. Efficacy of a synbiotic supplementation in the prevention of common winter diseases in children: a randomized, double-blind, placebo-controlled pilot study. Ther Adv Respir Dis. 2010; 4(5): 271-8.

86. Loesche W.J. Microbiology of dental decay and periodontal disease. In: Baron’s Medical Microbiology. 4th Ed. University of Texas Medical Branch; 1996.

87. Juneja A., Kakade A. Evaluating the effect of probiotic containing milk on salivary mutans streptococci levels. J Clin Pediatr Dent. 2012; 37(1): 9-14.

88. Näse L., Hatakka K., Savilahti E., et al. Effect of long-term consumption of a probiotic bacterium, Lactobacillus rhamnosus GG, in milk on dental caries and caries risk in children. Caries Res. 2001; 35(6): 412-20.

89. Yamashiro Y., Nagata S. Beneficial microbes for premature infants, and children with malignancy undergoing chemotherapy. Benef Microbes. 2010; 1(4): 357-65.

90. Tillisch K., Labus J., Kilpatrick L., et al. Consumption of fermented milk product with probiotic modulates brain activity. Gastroenterology. 2013; 144(7): 1394-401, 1401.e1-4.